Figure 9: Delivery of keratinocyte-targeted lipid nanoparticles encapsulating si-hnRNPA2B1 compromised the quality of wound closure.
(A) Transepidermal water loss (TEWL) after C57BL/6 mice treated with TLNPκ encapsulating either si-control or si-hnRNPA2B1. (n=10) (B) Representative coimmunofluorescence staining of loricrin with DAPI counterstaining in wound-edge tissue at day 10 post-wounding in C57BL/6 mice treated with either scramble or si-hnRNPA2B1 encapsulated keratinocyte targeted lipid nanoparticles. Scale, 200μm. Quantification of loricrin intensity in wound-edge tissue at day 10 post-wounding. Each dot corresponds to one quantified ROI, except the blue and red dots, which correspond to the mean of each mouse. At least 5 ROI per mouse. (n = 4) (C) TLNPκ/si-hnRNPA2B1 treatment compromised the expression of ZO-1 (green), ZO-2 (red), filaggrin (green) and occludin (red) in murine skin at day 10. Sections were counterstained with DAPI (blue). Dermal-epidermal junction is indicated by a dashed white line. Scale bars, 50 μm. The abundance of junctional proteins was quantified. Each dot corresponds to one quantified ROI, except the blue and red dots, which correspond to the mean of each mouse. At least 5 ROI per mouse. (n = 3, 4). Data expressed as mean ± SEM and were analyzed by two-tailed unpaired Student’s t-test.